Home > Insider Trading > Filing (0000912282-24-000628)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1790169	Flora Growth Corp.	FLGC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1955468	Clifford Starke	C/O Flora Growth Corp. 3230 W. Commercial Blvd., Suite 180 Fort Lauderdale FL 33309	Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2024-09-05	51	$0.95	474,046	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Appreciation Rights ("SARs")	Acquisiton	2023-12-15	1,028,665	$0.00	1,028,665	$1.21
Common Shares	Stock Appreciation Rights ("SARs")	Acquisiton	2024-08-14	575,319	$0.00	575,319	$0.92

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,028,665		2033-12-15	No	4	A	Direct
575,319		2034-08-14	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	565,714	Indirect	See footnote
Common Shares	300,347	Indirect	See footnote

Footnotes

Held by YT Research, Inc., a company in which the Reporting Person is the sole director and equity owner. The Reporting Person disclaims beneficial ownership of the securities held by YT Research, Inc. except to the extent of his pecuniary interest therein.
Held by Hampstead Private Capital Limited, a company in which the Reporting Person is the sole director and equity owner. The Reporting Person disclaims beneficial ownership of the securities held by Hampstead Private Capital Limited except to the extent of his pecuniary interest therein.
The SARs vest in 12 equal installments, subject to stock price criteria to be met prior to each tranche vesting. The SARs have a post-termination exercise period of one year.